WOPR-AI

NASDAQ:FBIO (Bullish)

Fortress Biotech, Inc.
Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Outstanding: 99.63 M
Capitalization: $299.88 M
Dividend: N/A
Entry Date (Eastern Time): 06/09/2026 @ 08:16
Entry Price: $2.65
Last Trade: $3.01
Cumulative SqueezeTrigger: $1.93
Fear Greed: 4.04
Earnings: $-1.54 (0.0x)
Sales: N/A
Book: $0.65 (4.6x)
Valuation Targets:
(2020-10-16) VV 
(2025-04-18) VE 
(2026-04-25) Y! 
$0.32 (0.1x)
$6.12 (2.0x)
$10.75 (3.6x)
Alpha Capture
  Year     Possible     Actual     Captured     FG/Ratio  
  2026   378.42%   25.8%   72.62%   6.366  
  2025   775.91%   72.64%   227.68%   1.522  
  2024   891.96%   25.73%   204.17%   1.094  
  2023   1276.13%   358.46%   2970.25%   -1.983  
  2022   1023.85%   74.51%   302.85%   -1.869  
  2021   778.86%   23.07%   119.95%   -1.005  
  2020   990.84%   16.97%   364.57%   -1.074  
  2019   1110.82%   150.45%   88.92%   -1.642  
  2018   863.38%   78.86%   155.45%   -1.656  
  2017   638.94%   42.5%   52.96%   3.885  
  2016   708.97%   3.57%   150.62%   1.327  

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Combined Graph (162 Days)


Investment Highlights

LAST TRADE: $3.01
SQUEEZETRIGGER: $ 1.93 - A short squeeze starts when stock crosses above this price.
VALUATION: $ 10.75
G ATS - Created on Wed, Jun 17th, 2026 at $2.93, with a target price of $3.68 by Wed, Jul 1st, 2026
P atternScan - Created on Mon, Jun 8th, 2026 at $2.65, with a target price of $3.1 by Sun, Jun 28th, 2026

ShortSqueeze

We have a proprietary database of all trading in US stocks and maintain massive databases of short sale and naked short sale time and sales data, along with short squeeze SqueezeTrigger prices. We are the only firm that knows the exact price that a short squeeze will start in every US stock.

The Cumulative Squeeze Trigger price for FBIO is $1.93.

This means that when FBIO closes above $1.93, we expect a short squeeze to begin that could quickly drive the price of FBIO considerably higher.


Friction Factor

Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. It shows us how many more shares of buying than selling it takes to move a stock higher by 1 cent, or how many more shares of selling than buying it takes to drop a stock by 1 cent. Here is how to understand Friction Factor:

  • If Friction Factor is positive, more buying than selling caused FBIO's price to rise
  • If Friction Factor is negative, more selling than buying caused FBIO's price to fall
  • If Friction Factor is 0, there was no discernable activity either way
  • If Friction Factor is abnormal, it means that more buying than selling caused the price to drop which is evidence of manipulative activity. In some cases more selling than buying can cause the price to increase. While this is rare, it must be noted as well. Friction Factor raw data.


Firing Predictions Details

GATS

FBIO Expected to Trade Up Short Term

June 17, 2026 / We are monitoring top equities trading strategies and these stocks are the most likely to trade Up in the coming weeks. Fortress Biotech, Inc. (NASDAQ:FBIO) is/are expected to go Up as Bullish signals have been generated by top equity trading strategies. This trading system is designed to identify high probability reversion to mean trading candidates. It looks to go long immediately following strong sell-offs, and goes short after sharp run ups. Its trades are short term and hone in on the irrational decisions of emotional traders around these extreme moves. The chart below displays the stocks expected to go Up and a suggested stop level to limit any potential trading losses.

Symbol  Company  Price  Stop Level
FBIO  Fortress Biotech, Inc.  $2.93  $2.82

PatternScan

FBIO Expected to Trade Up After Bullish Patterns Develop

June 8, 2026 / We are monitoring top technical trading patterns and these stocks are the most likely to trade Up in the coming weeks. Fortress Biotech, Inc. (NASDAQ:FBIO) is/are expected to go Up as Bullish signals have been generated by top technical trading patterns. We monitor these patterns: Support Break, Support Reversal, Breakaway Gap, Measured Gap, Exhaustion Gap, Resistance Break, Resistance Reversal, Saucer Reversal, Volume Climax, Volume Trend, Fibonacci Reversal, Consolidation Breaks, Trend Line Break,Trend Line Reversal, Candles, Golden Crosses, Death Crosses and more.
The chart below displays the stocks expected to go Up along with pattern, strategy and strength ratings.

Symbol  Company  Strategy  Pattern Name  Strength
FBIO  Fortress Biotech, Inc.  ARM6 Volatility Breakout  Engulfing Lines  3

Chart Pattern Recognition is based on a 20-year patterns database. This database is used to determine pattern strength for patterns as they appear. There is no optimization and the pattern signals never change. For each pattern variation, we record accuracy and profitability statistics in a patterns database. From this information, we are able to define strength ratings from 1 to 5. The '1' rating shows ALL patterns while a '5' rating shows the best patterns according to profitability. Each pattern has its own strength rating factors. The result is an automatic ranking system that allows us to only show the BEST patterns. You can see that, at Strength 5, virtually all the patterns are profitable. The pattern strength rating system separates the most profitable patterns.


Previous Reports

G ATS - Created on Wed, Jun 17th, 2026 at $2.93, with a target price of $3.68 by Wed, Jul 1st, 2026
P atternScan - Created on Mon, Jun 8th, 2026 at $2.65, with a target price of $3.1 by Sun, Jun 28th, 2026
G roup Correlation - Created on Fri, May 22nd, 2026 at $2.76, with a target price of $3.29 by Fri, Jun 19th, 2026
P atternScan - Created on Thu, May 14th, 2026 at $2.23, with a target price of $2.61 by Wed, Jun 3rd, 2026
G roup Correlation - Created on Mon, May 11th, 2026 at $2.38, with a target price of $1.96 by Mon, Jun 8th, 2026
P atternScan - Created on Wed, Apr 15th, 2026 at $2.42, with a target price of $2.84 by Tue, May 5th, 2026
P atternScan - Created on Thu, Apr 2nd, 2026 at $2.47, with a target price of $2.89 by Wed, Apr 22nd, 2026
P atternScan - Created on Tue, Mar 24th, 2026 at $2.98, with a target price of $3.48 by Mon, Apr 13th, 2026
P atternScan - Created on Mon, Mar 23rd, 2026 at $3.00, with a target price of $3.51 by Sun, Apr 12th, 2026
P atternScan - Created on Thu, Mar 5th, 2026 at $3.10, with a target price of $3.63 by Wed, Mar 25th, 2026
P atternScan - Created on Wed, Feb 11th, 2026 at $3.75, with a target price of $4.38 by Tue, Mar 3rd, 2026
P atternScan - Created on Wed, Feb 4th, 2026 at $3.09, with a target price of $3.61 by Tue, Feb 24th, 2026
G roup Correlation - Created on Tue, Jan 20th, 2026 at $3.70, with a target price of $4.47 by Tue, Feb 17th, 2026
P atternScan - Created on Fri, Jan 16th, 2026 at $3.48, with a target price of $2.84 by Thu, Feb 5th, 2026
P atternScan - Created on Wed, Jan 14th, 2026 at $3.88, with a target price of $3.17 by Tue, Feb 3rd, 2026
G ATS - Created on Mon, Dec 22nd, 2025 at $3.54, with a target price of $5.3 by Mon, Jan 5th, 2026
P atternScan - Created on Wed, Dec 17th, 2025 at $3.51, with a target price of $4.09 by Tue, Jan 6th, 2026
G ATS - Created on Wed, Dec 17th, 2025 at $3.51, with a target price of $5.25 by Wed, Dec 31st, 2025
P atternScan - Created on Mon, Nov 10th, 2025 at $2.61, with a target price of $3.04 by Sun, Nov 30th, 2025
P atternScan - Created on Thu, Nov 6th, 2025 at $2.48, with a target price of $2.89 by Wed, Nov 26th, 2025
P atternScan - Created on Thu, Oct 16th, 2025 at $2.77, with a target price of $3.23 by Wed, Nov 5th, 2025
G roup Correlation - Created on Mon, Oct 6th, 2025 at $2.75, with a target price of $3.35 by Mon, Nov 3rd, 2025
P atternScan - Created on Mon, Oct 6th, 2025 at $2.75, with a target price of $3.2 by Sun, Oct 26th, 2025
P atternScan - Created on Thu, Sep 18th, 2025 at $3.45, with a target price of $2.82 by Wed, Oct 8th, 2025
P atternScan - Created on Thu, Sep 4th, 2025 at $2.95, with a target price of $3.36 by Wed, Sep 24th, 2025
G ATS - Created on Tue, Sep 2nd, 2025 at $2.58, with a target price of $2.8 by Mon, Sep 15th, 2025
P atternScan - Created on Tue, Sep 2nd, 2025 at $2.58, with a target price of $2.93 by Mon, Sep 22nd, 2025
S queezeTrigger - Created on Thu, Aug 28th, 2025 at $2.49, with a target price of $3.01 by Wed, Oct 8th, 2025
P atternScan - Created on Fri, Aug 22nd, 2025 at $2.24, with a target price of $1.84 by Thu, Sep 11th, 2025
P atternScan - Created on Thu, Aug 14th, 2025 at $1.93, with a target price of $2.2 by Wed, Sep 3rd, 2025
G roup Correlation - Created on Tue, Jul 15th, 2025 at $1.96, with a target price of $1.58 by Tue, Aug 12th, 2025
P atternScan - Created on Mon, Jun 30th, 2025 at $1.82, with a target price of $2.06 by Sun, Jul 20th, 2025
P atternScan - Created on Thu, Jun 26th, 2025 at $1.80, with a target price of $2.04 by Wed, Jul 16th, 2025


Report Statistics

Avg ReturnAvg Maturity DaysHitsMisses% Accuracy

Insider

  29.20%181.71514784494.7%

Seasonality

  10.84%27.7418867986.0%

Group Correlation

  10.47%27.926568502584.1%

Analyst

  21.34%61.566614182.5%

Events

  6.78%20.9691681.2%

PatternScan

  17.69%20.647536112981978.5%

GATS

  9.01%13.91016212930177.6%

Earnings

  11.53%28.862422373.7%

Friction Factor

  11.39%6.98105304672.7%

SqueezeTrigger

  20.75%41.51113135028168.9%

Past performance may not be indicative of future results. Different types of investments involve varying degrees of risk. Therefore, it should not be assumed that future performance of any specific investment or investment strategy (including the investments and/or investment strategies recommended or undertaken by WOPR or its affiliates (collectively, "WOPR")) will be profitable or equal the corresponding indicated performance level(s). Moreover, you should not assume that any of the above content serves as the receipt of, or as a substitute for, personalized investment advice from WOPR. A copy of our current written disclosure statement discussing our services and fees continues to remain available for your review upon request. Historical performance results for investment indices and/or categories have been provided for general comparison purposes only using computer simulations, and generally do not reflect the deduction of transaction and/or custodial fees, the deduction of an investment management fee, nor the impact of taxes, the incurrence of which would have the effect of decreasing historical performance results. It should not be assumed that your account holdings do or will correspond directly to any comparative indices.


Report Descriptions

Insider

  Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders

Seasonality

  Predicts probability, price move and length of move based on exact time of year for all US stocks

Group Correlation

  Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups

Analyst

  Records and tracks the rating calls of over 5000 analysts

Events

  Tracks patterns directly correlated to specific events.

PatternScan

  Automates tracking of every technical pattern and predicts next move in stocks.

GATS

  Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.

Earnings

  Predicts probability, price move and length of move before and after all US stock earnings reports

Friction Factor

  Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

SqueezeTrigger

  Tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.


Legal / Disclaimer

Our research gives institutional and individual investors an exclusive advantage in making precise, predictive and profitable trading decisions. Our proprietary technologies "Earnings, Seasonality, Squeeze Trigger, Group Sector and GATS" apply artificial intelligence, proprietary algorithms, market data and research to help our clients realize exponential returns.

All material herein was automatically prepared by our servers based on current and historical statistical facts containing no human intervention or bias of any sort and is based upon information believed to be reliable. Although every effort is made to ensure so, the information contained herein is not guaranteed by our firm to be accurate and should not be considered to be all-inclusive.

The companies that are discussed in this report have not approved the statements made herrein. This report contains forward-looking statements based on current and historical statistics, and involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Our firm is not a registered investment advisor. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

Our firm or our affiliates may receive compensation from independent third parties, or from the companies mentioned, for data provided in this report or related services.

Our affiliates, officers, directors and employees do not own shares of the company mentioned in this report, but may from time to time buy/sell the shares discussed in this report and may profit from those trades.

Our firm will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment.

Report Generated on Sat, 20 Jun 2026 11:20:33 -0700, All Rights Reserved. © 2026